推薦產品
等級
pharmaceutical primary standard
API 家族
doxorubicin
製造商/商標名
EDQM
mp
216 °C (dec.) (lit.)
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
Cl[H].COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
InChI
1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1
InChI 密鑰
MWWSFMDVAYGXBV-RUELKSSGSA-N
基因資訊
human ... TOP2A(7153)
尋找類似的產品? 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Produced by certain strains of Streptomyces coeruleorubidus or Streptomyces peucetius or obtained by any other means.
For further information and support please go to the website of the issuing Pharmacopoeia.
Produced by certain strains of Streptomyces coeruleorubidus or Streptomyces peucetius or obtained by any other means.
應用
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
- Reference solutions (b) and (c) in the testing of related substances in daunorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0662
- Reference solutions (a) and (c) to test related substances in doxorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0714
- Reference solutions (b) and (c) in the testing of related substances in epirubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 1590
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險分類
Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
客戶也查看了
Doxorubicin hydrochloride
European pharmacopoeia, 2471-2472 (2008)
Daunorubicin hydrochloride
European pharmacopoeia, 2343-2344 (2008)
Epirubicin hydrochloride
European pharmacopoeia, 4974-4975 (2021)
Materials science & engineering. C, Materials for biological applications, 103, 109838-109838 (2019-07-28)
The objective of the study was to obtain multifunctional core shell nanostructures of superparamagnetic iron oxide nanoparticles (Fe3O4) coated with various ionic biopolymers that can optimize toxicity to healthy cells, colloidal instabilities and drug loading capacities. These nanostructures can also
Health technology assessment (Winchester, England), 10(9), 1-132 (2006-03-21)
To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent treatment of advanced ovarian cancer.
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務